Collegium Pharma (COLL) Misses Q4 EPS by $1.77

Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.73), $1.77 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $27.36 million versus the consensus estimate of $81.61 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• Green Dot and CommerceOne shareholders approve acquisition deal